Literature DB >> 15579185

Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals.

Giacomo Zoppini1, Giovanni Targher, Cristina Venturi, Cristina Zamboni, Michele Muggeo.   

Abstract

OBJECTIVES: To examine the association between nonalcoholic hepatic steatosis (HS) and the activity of the hypothalamo-pituitary-adrenal (HPA) axis, as evaluated by a low-dose dexamethasone suppression test, in obese subjects. DESIGN AND PATIENTS: In a cross-sectional study, we examined 54 obese, otherwise healthy, individuals with a negligible or zero daily alcohol consumption. MEASUREMENTS: HS (by ultrasonography), glucose tolerance status (by oral glucose load), insulin resistance [by homeostasis model assessment (HOMA)] and 1.0 mg postdexamethasone (postdex) suppression cortisol levels were measured.
RESULTS: Subjects with nonalcoholic HS (n = 39) had markedly less suppressed circulating cortisol levels than those without HS (n = 15) (21.9 +/- 2.6 vs. 11.0 +/- 1.4 nmol/l, P < 0.001). In addition, subjects with nonalcoholic HS had significantly higher values of HOMA-insulin resistance score and circulating liver enzymes than their counterparts without HS. Age, body mass index (BMI), waist/hip ratio, plasma glucose concentration (both at fasting and after glucose load), lipids and blood pressure values did not differ significantly between the groups. Females were more represented among those without HS. The marked differences in postdex suppression cortisol levels that were observed between the groups were little affected by adjustment for sex, age, BMI, waist/hip ratio, HOMA-insulin resistance score, plasma lipids and liver enzyme levels. Similarly, in a logistic regression analysis, cortisol levels significantly predicted the presence of nonalcoholic HS (P = 0.032), independently of potential confounders.
CONCLUSIONS: These results suggest that nonalcoholic hepatic steatosis is closely correlated with a subtle, chronic activation of the HPA axis in obese, otherwise healthy, individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579185     DOI: 10.1111/j.1365-2265.2004.02154.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  7 in total

Review 1.  Mechanisms of glucocorticoid-induced insulin resistance: focus on adipose tissue function and lipid metabolism.

Authors:  Eliza B Geer; Julie Islam; Christoph Buettner
Journal:  Endocrinol Metab Clin North Am       Date:  2014-03       Impact factor: 4.741

Review 2.  The pituitary-adrenal axis and body composition.

Authors:  Eva Fernandez-Rodriguez; Paul M Stewart; Mark S Cooper
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

3.  The impact of cortisol in steatotic and non-steatotic liver surgery.

Authors:  María Eugenia Cornide-Petronio; Esther Bujaldon; Mariana Mendes-Braz; Cindy G Avalos de León; Mónica B Jiménez-Castro; Ana I Álvarez-Mercado; Jordi Gracia-Sancho; Juan Rodés; Carmen Peralta
Journal:  J Cell Mol Med       Date:  2017-04-04       Impact factor: 5.310

4.  NAFLD Aggravates Septic Shock Due to Inadequate Adrenal Response and 11β-HSDs Dysregulation in Rats.

Authors:  Hui-Chun Huang; Ming-Hung Tsai; Fa-Yauh Lee; Te-Yueh Lin; Ching-Chih Chang; Chiao-Lin Chuang; Shao-Jung Hsu; Ming-Chih Hou; Yi-Hsiang Huang
Journal:  Pharmaceutics       Date:  2020-04-28       Impact factor: 6.321

Review 5.  Nonalcoholic Fatty Liver Disease and Endocrine Axes-A Scoping Review.

Authors:  Madalena Von-Hafe; Marta Borges-Canha; Catarina Vale; Ana Rita Leite; João Sérgio Neves; Davide Carvalho; Adelino Leite-Moreira
Journal:  Metabolites       Date:  2022-03-29

6.  Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men.

Authors:  H B Holt; S H Wild; A D Postle; J Zhang; G Koster; M Umpleby; F Shojaee-Moradie; K Dewbury; P J Wood; D I Phillips; C D Byrne
Journal:  Diabetologia       Date:  2007-03-17       Impact factor: 10.122

7.  Effects of Mifepristone on Nonalcoholic Fatty Liver Disease in a Patient with a Cortisol-Secreting Adrenal Adenoma.

Authors:  Enzo Ragucci; Dat Nguyen; Michele Lamerson; Andreas G Moraitis
Journal:  Case Rep Endocrinol       Date:  2017-11-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.